Author:
Baert T.,Ferrero A.,Sehouli J.,O'Donnell D.M.,González-Martín A.,Joly F.,van der Velden J.,Blecharz P.,Tan D.S.P.,Querleu D.,Colombo N.,du Bois A.,Ledermann J.A.
Reference120 articles.
1. ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease;Colombo;Ann Oncol,2019
2. Randomized phase III study to evaluate the impact of secondary cytoreductive surgery in recurrent ovarian cancer: final analysis of AGO DESKTOP III/ENGOT-ov20;du Bois;J Clin Oncol,2020
3. Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials;Blackledge;Br J Cancer,1989
4. Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds;Gore;J Clin Oncol,1990
5. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin;Markman;J Clin Oncol,1991
Cited by
59 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献